Elevance Health Inc. (ELV) compounding analysis
Full-size annual and quarterly year-over-year growth charts for revenue, EPS, operating cash flow, EBITDA, and free cash flow against the 15%, 20%, and 30% bars over 3-, 5-, and 10-year windows, with each metric's valuation multiple vs its own history.
Revenue · 10YDoes not currently clear the 15%+, 20%+, or 30%+ revenue bars over 10Y.
- Score
- 22/100
- 10Y CAGR
- 9.7%
- Median YoY
- 9.5%
- YoY volatility
- σ 5.6pp· smooth
- Quarters ≥ 20%
- 1 of 40
- Negative quarters
- 1
- Valuation vs own 10Y history
- P/S 0.4x · 10Y median 0.7x · 14th percentile · as of Aug 19, 2026
How this score is computed
- Quarters at or above 20%: 1 of 40 → 1 of 40 pts
- Steadiness (typical swing 5.6pp) → 21 of 25 pts
- Pace (median 9.5% YoY) → 0 of 20 pts
- Latest quarter (1.4% YoY) → 0 of 15 pts
- Score: 22 of 100
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Across metrics · 10Y
| Metric | 10Y CAGR | Median YoY | YoY σ | Qtrs ≥ 20% | Neg. qtrs |
|---|---|---|---|---|---|
| RevenueRevenue | 9.7% | 9.5% | 5.6pp | 1 of 40 | 1 |
| EPSEPS | 10.4% | 11.3% | 108.4pp | 15 of 40 | 13 |
| Op cash flowOperating cash flow | 0.4% | 0.5% | 124.9pp | 15 of 34 | 17 |
| EBITDAEBITDA | 4.4% | 5.3% | 39.7pp | 9 of 40 | 18 |
| FCFFree cash flow | -1% | -0.4% | 289.0pp | 14 of 33 | 17 |
Reported figures over 10Y: annual-series CAGR, median and standard deviation (σ, percentage points) of quarterly year-over-year growth, quarters at or above 20%, and quarters with negative YoY. “—” means the window needs more comparable data.
Scores, qualification bars, and the 0–100 consistency methodology are documented on the compounders list page →
See also: ELV on the compounders surface · All compounders, ranked